{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:51:14Z","timestamp":1791478274881,"version":"4.3.4"},"reference-count":37,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2025-0727_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Gonadotropin-releasing hormone analogues (GnRHa) are the standard treatment for central precocious puberty (CPP), with well-established efficacy but uncommon escape phenomena. We report an escape case in hypothalamic hamartoma (HH)-related CPP and review the literature on HH-related CPP and idiopathic central precocious puberty (ICPP), analyzing characteristics of escape\u00a0cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0727_abs_002\">\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 15-month-old boy with HH-related CPP experienced escape during GnRHa therapy. Despite dose escalation and switching the drug type and formulation, suppression of the hypothalamic-pituitary-gonadal (HPG) axis remained incomplete. Combination therapy with an aromatase inhibitor and an androgen receptor antagonist ultimately controlled hyperandrogenic symptoms, including acne and frequent erections, while decelerating growth velocity and bone age progression. He developed epilepsy at 38\u00a0months of age and is scheduled for surgery. Literature review indicates that approximately 8.9\u202f% of HH-related CPP cases experience escape, some of which are associated with impaired drug absorption or inadequate dosing. In ICPP, escape is predominantly a mild, biochemical phenomenon without significant impact on long-term outcomes like bone age control or predicted adult height.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0727_abs_003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with HH-related CPP should be monitored for the risk of escape during GnRHa therapy. The underlying mechanism may involve relatively inadequate GnRHa exposure, potentially attributable to abnormal neuroendocrine activity of the HH lesion itself. Within safe limits, individualized dose titration is a rational approach to achieving adequate suppression. For patients refractory to GnRHa, combining therapy with peripheral androgen inhibitors is a potential option; however, given the current lack of long-term safety data, a monitoring protocol for adverse effects is essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2025-0727","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:57:05Z","timestamp":1782889025000},"page":"1051-1059","source":"Crossref","is-referenced-by-count":0,"title":["Reflections on GnRH analogues dosage in the context of escape phenomenon: a case report of hypothalamic hamartoma with central precocious puberty and literature review"],"prefix":"10.1515","volume":"39","author":[{"given":"Xinmeng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Genetics and Metabolism , Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Genetics and Metabolism , Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Genetics and Metabolism , Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyu","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Peking University First Hospital , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiu","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Genetics and Metabolism , Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026100815572194581_j_jpem-2025-0727_ref_001","doi-asserted-by":"crossref","unstructured":"Mitrica, M, Manole, AM, Toma, M, Sirbu, OM, Sirbu, AM, Munteanu, AE. Hypothalamic hamartomas: a narrative review. Biomedicines 2025;13:371. https:\/\/doi.org\/10.3390\/biomedicines13020371.","DOI":"10.3390\/biomedicines13020371"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_002","doi-asserted-by":"crossref","unstructured":"Suh, J, Choi, Y, Oh, JS, Song, K, Choi, HS, Kwon, A, et al.. Management of central precocious puberty in children with hypothalamic hamartoma. Children (Basel) 2021;8:711. https:\/\/doi.org\/10.3390\/children8080711.","DOI":"10.3390\/children8080711"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_003","doi-asserted-by":"crossref","unstructured":"Jung, H, Carmel, P, Schwartz, MS, Witkin, JW, Bentele, KH, Westphal, M, et al.. Some hypothalamic hamartomas contain transforming growth factor alpha, a puberty-inducing growth factor, but not luteinizing hormone-releasing hormone neurons. J\u00a0Clin Endocrinol Metab 1999;84:4695\u2013701. https:\/\/doi.org\/10.1210\/jcem.84.12.6185.","DOI":"10.1210\/jc.84.12.4695"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_004","doi-asserted-by":"crossref","unstructured":"de Brito, VN, Latronico, AC, Arnhold, IJ, Lo, LS, Domenice, S, Albano, MC, et al.. Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. Arch Dis Child 1999;80:231\u20134. https:\/\/doi.org\/10.1136\/adc.80.3.231.","DOI":"10.1136\/adc.80.3.231"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_005","doi-asserted-by":"crossref","unstructured":"Stewart, L, Steinbok, P, Daaboul, J. Role of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty. Report of six cases. J\u00a0Neurosurg 1998;88:340\u20135. https:\/\/doi.org\/10.3171\/jns.1998.88.2.0340.","DOI":"10.3171\/jns.1998.88.2.0340"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_006","unstructured":"Roszkowski, M, Wolska, A, Drabik, K, Grajkowska, W. [Surgical treatment of GnRH secretory hypothalamic hamartomas causing precocious puberty]. Neurol Neurochir Pol 1999;33:587\u2013602."},{"key":"2026100815572194581_j_jpem-2025-0727_ref_007","doi-asserted-by":"crossref","unstructured":"Starceski, PJ, Lee, PA, Albright, AL, Migeon, CJ. Hypothalamic hamartomas and sexual precocity. Evaluation of treatment options. Am J Dis Child 1990;144:225\u20138. https:\/\/doi.org\/10.1001\/archpedi.1990.02150260105040.","DOI":"10.1001\/archpedi.1990.02150260105040"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_008","doi-asserted-by":"crossref","unstructured":"Luo, X, Hou, L, Zhong, Y, You, C, Yang, Y, Wu, X, et al.. An open label, multicenter clinical trial that investigated the efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children. Medicine (Baltim) 2021;100:e28158. https:\/\/doi.org\/10.1097\/md.0000000000028158.","DOI":"10.1097\/MD.0000000000028158"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_009","doi-asserted-by":"crossref","unstructured":"Vurall\u0131, D, Alika\u015fifo\u011flu, A, \u0130yig\u00fcn, \u0130, Canoru\u00e7, D, Ozon, A, G\u00f6n\u00e7, N, et al.. Treatment with depot leuprolide acetate in girls with idiopathic precocious puberty: what parameter should be used in deciding on the initial dose? J\u00a0Clin Res Pediatr Endocrinol 2020;12:37\u201344. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2019.2019.0060.","DOI":"10.4274\/jcrpe.galenos.2019.2019.0060"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_010","doi-asserted-by":"crossref","unstructured":"Klein, K, Yang, J, Aisenberg, J, Wright, N, Kaplowitz, P, Lahlou, N, et al.. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J\u00a0Pediatr Endocrinol Metab 2016;29:1241\u20138. https:\/\/doi.org\/10.1515\/jpem-2015-0376.","DOI":"10.1515\/jpem-2015-0376"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_011","doi-asserted-by":"crossref","unstructured":"Freire, AV, Gryngarten, MG, Ballerini, MG, Arcari, AJ, Escobar, ME, Bergad\u00e1, I, et al.. Assessment of estradiol response after depot triptorelin administration in girls with central precocious puberty. Horm Res Paediatr 2016;85:58\u201364. https:\/\/doi.org\/10.1159\/000442523.","DOI":"10.1159\/000442523"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_012","doi-asserted-by":"crossref","unstructured":"Lee, PA, Klein, K, Mauras, N, Lev-Vaisler, T, Bacher, P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J\u00a0Clin Endocrinol Metab 2014;99:3153\u20139. https:\/\/doi.org\/10.1210\/jc.2013-4471.","DOI":"10.1210\/jc.2013-4471"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_013","doi-asserted-by":"crossref","unstructured":"Lee, PA, Klein, K, Mauras, N, Neely, EK, Bloch, CA, Larsen, L, et al.. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J\u00a0Clin Endocrinol Metab 2012;97:1572\u201380. https:\/\/doi.org\/10.1210\/jc.2011-2704.","DOI":"10.1210\/jc.2011-2704"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_014","doi-asserted-by":"crossref","unstructured":"Mericq, V, Lammoglia, JJ, Unanue, N, Villaroel, C, Hern\u00e1ndez, MI, Avila, A, et al.. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. Clin Endocrinol 2009;71:686\u201390. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03584.x.","DOI":"10.1111\/j.1365-2265.2009.03584.x"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_015","doi-asserted-by":"crossref","unstructured":"Thaneetrakool, T, Aroonparkmongkol, S, Numsriskulrat, N, Supornsilchai, V, Wacharasindhu, S, Srilanchakon, K. Efficacy of leuprolide acetate versus triptorelin pamoate administered every 3\u00a0months for treatment of central precocious puberty. Clin Exp Pediatr 2025;68:91\u20136. https:\/\/doi.org\/10.3345\/cep.2024.00822.","DOI":"10.3345\/cep.2024.00822"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_016","doi-asserted-by":"crossref","unstructured":"Thaneetrakool, T, Aroonparkmongkol, S, Numsriskulrat, N, Supornsilchai, V, Wacharasindhu, S, Srilanchakon, K. Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment. Front Endocrinol (Lausanne) 2024;15:1390674. https:\/\/doi.org\/10.3389\/fendo.2024.1390674.","DOI":"10.3389\/fendo.2024.1390674"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_017","doi-asserted-by":"crossref","unstructured":"Park, KH, Gwag, SH, Kim, YJ, Chung, LY, Kang, E, Nam, HK, et al.. Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2024;29:161\u20136. https:\/\/doi.org\/10.6065\/apem.2346132.066.","DOI":"10.6065\/apem.2346132.066"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_018","doi-asserted-by":"crossref","unstructured":"Huang, S, Zhang, L, Gao, C, Ou, H, Hou, L, Liu, Z, et al.. Efficacy and safety of leuprorelin 3-month depot (11.25\u00a0mg) for idiopathic central precocious puberty treatment of Chinese girls: a single-center retrospective study. J\u00a0Pediatr Endocrinol Metab 2024;37:15\u201320. https:\/\/doi.org\/10.1515\/jpem-2023-0410.","DOI":"10.1515\/jpem-2023-0410"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_019","doi-asserted-by":"crossref","unstructured":"Ni, MM, Yang, ST, Sun, JY, Wu, WW, Li, M, Gu, W, et al.. Efficacy of first-year GnRHa therapy in girls with idiopathic central precocious puberty diagnosed after age 8: a retrospective study. Gynecol Endocrinol 2025;41:2500481. https:\/\/doi.org\/10.1080\/09513590.2025.2500481.","DOI":"10.1080\/09513590.2025.2500481"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_020","doi-asserted-by":"crossref","unstructured":"Jeon, MJ, Choe, JW, Chung, HR, Kim, JH. Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2021;26:171\u20137. https:\/\/doi.org\/10.6065\/apem.2040134.067.","DOI":"10.6065\/apem.2040134.067"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_021","doi-asserted-by":"crossref","unstructured":"Chung, LY, Kang, E, Nam, HK, Rhie, YJ, Lee, KH. Efficacy of triptorelin 3-Month depot compared to 1-Month depot for the treatment of Korean girls with central precocious puberty in single tertiary center. J\u00a0Kor Med Sci 2021;36:e219. https:\/\/doi.org\/10.3346\/jkms.2021.36.e219.","DOI":"10.3346\/jkms.2021.36.e219"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_022","doi-asserted-by":"crossref","unstructured":"Wiromrat, P, Panamonta, O. Elevated random luteinizing hormone is an unreliable indicator for pubertal suppression in girls treated with monthly leuprolide for idiopathic central precocious puberty. J\u00a0Clin Res Pediatr Endocrinol 2019;11:227\u201333. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2018.2018.0213.","DOI":"10.4274\/jcrpe.galenos.2018.2018.0213"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_023","doi-asserted-by":"crossref","unstructured":"Li, WJ, Gong, CX, Guo, MJ, Xing, J, Li, T, Song, WH, et al.. Efficacy and safety of domestic leuprorelin in girls with idiopathic central precocious puberty: a multicenter, randomized, parallel, controlled trial. Chin Med J (Engl) 2015;128:1314\u201320. https:\/\/doi.org\/10.4103\/0366-6999.156773.","DOI":"10.4103\/0366-6999.156773"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_024","doi-asserted-by":"crossref","unstructured":"Kim, YJ, Lee, HS, Lee, YJ, Lim, JS, Kim, SY, Kim, EY, et al.. Multicenter clinical trial of leuprolide acetate depot (luphere depot 3.75\u00a0mg) for efficacy and safety in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2013;18:173\u20138. https:\/\/doi.org\/10.6065\/apem.2013.18.4.173.","DOI":"10.6065\/apem.2013.18.4.173"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_025","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Aguayo, A, Hern\u00e1ndez, MI, Beas, F, I\u00f1iguez, G, Avila, A, Sovino, H, et al.. Treatment of central precocious puberty with triptorelin 11.25\u00a0mg depot formulation. J\u00a0Pediatr Endocrinol Metab 2006;19:963\u201370. https:\/\/doi.org\/10.1515\/jpem.2006.19.8.963.","DOI":"10.1515\/JPEM.2006.19.8.963"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_026","doi-asserted-by":"crossref","unstructured":"Carel, JC, Blumberg, J, Seymour, C, Adamsbaum, C, Lahlou, N. Three-month sustained-release triptorelin (11.25\u00a0mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006;154:119\u201324. https:\/\/doi.org\/10.1530\/eje.1.02056.","DOI":"10.1530\/eje.1.02056"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_027","doi-asserted-by":"crossref","unstructured":"Zevin, EL, Eugster, EA. Central precocious puberty: a review of diagnosis, treatment, and outcomes. Lancet Child Adolesc Health 2023;7:886\u201396. https:\/\/doi.org\/10.1016\/s2352-4642(23)00237-7.","DOI":"10.1016\/S2352-4642(23)00237-7"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_028","doi-asserted-by":"crossref","unstructured":"Brito, VN, Canton, APM, Seraphim, CE, Abreu, AP, Macedo, DB, Mendonca, BB, et al.. The congenital and acquired mechanisms implicated in the etiology of central precocious puberty. Endocr Rev 2023;44:193\u2013221. https:\/\/doi.org\/10.1210\/endrev\/bnac020.","DOI":"10.1210\/endrev\/bnac020"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_029","doi-asserted-by":"crossref","unstructured":"Harrison, VS, Oatman, O, Kerrigan, JF. Hypothalamic hamartoma with epilepsy: review of endocrine comorbidity. Epilepsia 2017;58:S50\u201359. https:\/\/doi.org\/10.1111\/epi.13756.","DOI":"10.1111\/epi.13756"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_030","doi-asserted-by":"crossref","unstructured":"Chan, YM, Fenoglio-Simeone, KA, Paraschos, S, Muhammad, L, Troester, MM, Ng, YT, et al.. Central precocious puberty due to hypothalamic hamartomas correlates with anatomic features but not with expression of GnRH, TGFalpha, or KISS1. Horm Res Paediatr 2010;73:312\u20139. https:\/\/doi.org\/10.1159\/000308162.","DOI":"10.1159\/000308162"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_031","doi-asserted-by":"crossref","unstructured":"Jin, P, Zhang, Y, Zhu, X, Wu, A. Efficacy and safety of different doses of gonadotropin-releasing hormone analogues in the treatment of precocious puberty in children: a systematic review and meta-analysis. Transl Pediatr 2025;14:92\u2013103. https:\/\/doi.org\/10.21037\/tp-24-439.","DOI":"10.21037\/tp-24-439"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_032","unstructured":"[Expert consensus on the diagnosis and treatment of central precocious puberty (2022)]. Zhonghua Er Ke Za Zhi 2023;61:16\u201322."},{"key":"2026100815572194581_j_jpem-2025-0727_ref_033","doi-asserted-by":"crossref","unstructured":"Kim, SJ, Kim, JH, Hong, YH, Chung, IH, Lee, EB, Kang, E, et al.. 2022 clinical practice guidelines for central precocious puberty of Korean children and adolescents. Ann Pediatr Endocrinol Metab 2023;28:168\u201377. https:\/\/doi.org\/10.6065\/apem.2346168.084.","DOI":"10.6065\/apem.2346168.084"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_034","doi-asserted-by":"crossref","unstructured":"Torres-Tamayo, M, Zurita-Cruz, JN, Aguilar-Herrera, BE, Miranda-Lora, AL, Calzada-Le\u00f3n, R, Rivera-Hern\u00e1ndez, AJ, et al.. Puberty blockade: clinical guideline for the diagnosis and treatment of precocious puberty. Bol Med Hosp Infant Mex 2020;77:S19\u201325. https:\/\/doi.org\/10.24875\/BMHIM.20000085.","DOI":"10.24875\/BMHIM.20000083"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_035","doi-asserted-by":"crossref","unstructured":"Bangalore Krishna, K, Fuqua, JS, Rogol, AD, Klein, KO, Popovic, J, Houk, CP, et al.. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr 2019;91:357\u201372. https:\/\/doi.org\/10.1159\/000501336.","DOI":"10.1159\/000501336"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_036","doi-asserted-by":"crossref","unstructured":"Gurnurkar, S, DiLillo, E, Carakushansky, M. A case of familial male-limited precocious puberty with a novel mutation. J\u00a0Clin Res Pediatr Endocrinol 2021;13:239\u201344. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2020.2020.0067.","DOI":"10.4274\/jcrpe.galenos.2020.2020.0067"},{"key":"2026100815572194581_j_jpem-2025-0727_ref_037","doi-asserted-by":"crossref","unstructured":"Li, CD, Luo, SQ, Gong, J, Ma, ZY, Jia, G, Zhang, YQ, et al.. Surgical treatment of hypothalamic hamartoma causing central precocious puberty: long-term follow-up. J\u00a0Neurosurg Pediatr 2013;12:151\u20134. https:\/\/doi.org\/10.3171\/2013.4.peds12617.","DOI":"10.3171\/2013.4.PEDS12617"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0727\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0727\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:58:06Z","timestamp":1791475086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0727\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,10,26]]}},"alternative-id":["10.1515\/jpem-2025-0727"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2025-0727","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}